New Phase 2 Study of Cancer and COVID-19

Cancer Research Institute and RevImmune announced dosing of the first patient in new phase 2 study assessing therapeutic benefit of interleukin-7 (IL-7) in patients with cancer and COVID-19. This is the first study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus, who are at increased risk of progressing to severe stages of COVID-19. Since the emergence of COVID-19 one year ago, a growing understanding of the important role of the immune system’s cellular response, including T cell fitness, in patients with COVID-19 has shifted treatment focus away from solely using immunosuppressive drugs to addressing the insufficient immune response as this trial aims to do.
 

DISCOVER IL-7